MA46742A - Composition pharmaceutique, méthodes de traitement et leurs utilisations - Google Patents

Composition pharmaceutique, méthodes de traitement et leurs utilisations

Info

Publication number
MA46742A
MA46742A MA046742A MA46742A MA46742A MA 46742 A MA46742 A MA 46742A MA 046742 A MA046742 A MA 046742A MA 46742 A MA46742 A MA 46742A MA 46742 A MA46742 A MA 46742A
Authority
MA
Morocco
Prior art keywords
treatment
methods
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
MA046742A
Other languages
English (en)
Inventor
Uli Christian Broedl
Eynatten Maximilian Von
Hans-Juergen Woerle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA46742A publication Critical patent/MA46742A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046742A 2016-11-10 2017-11-08 Composition pharmaceutique, méthodes de traitement et leurs utilisations MA46742A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420062P 2016-11-10 2016-11-10
US201762514249P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
MA46742A true MA46742A (fr) 2019-09-18

Family

ID=60293959

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046742A MA46742A (fr) 2016-11-10 2017-11-08 Composition pharmaceutique, méthodes de traitement et leurs utilisations

Country Status (13)

Country Link
US (4) US20180125813A1 (fr)
EP (1) EP3538107A1 (fr)
JP (2) JP2019533709A (fr)
KR (2) KR20190084096A (fr)
CN (1) CN109922813A (fr)
AU (2) AU2017357589B2 (fr)
BR (1) BR112019008384A2 (fr)
CA (1) CA3039745A1 (fr)
CL (1) CL2019001214A1 (fr)
MA (1) MA46742A (fr)
MX (2) MX2019005435A (fr)
PH (1) PH12019501018A1 (fr)
WO (1) WO2018087132A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UY32441A (es) 2009-02-13 2010-09-30 Boehringer Ingelheim Int Composicion farmaceutica, metodos de tratamiento y sus usos
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
CR20210222A (es) * 2020-07-27 2022-08-29 Astrazeneca Ab Métodos de tratamiento de enfermedad renal crónica con dapagliflozina
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
EP4447961A1 (fr) * 2021-12-14 2024-10-23 Boehringer Ingelheim International GmbH Inhibiteurs de l'aldostérone synthase pour le traitement d'une néphropathie chronique

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103467423B (zh) 2004-03-16 2016-03-16 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
NZ594024A (en) 2009-02-13 2013-08-30 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CA2775961C (fr) 2009-09-30 2017-11-07 Boehringer Ingelheim International Gmbh Procede de preparation d'une forme cristalline de 1-chloro-4-(beta-d-gluucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene
WO2011039108A2 (fr) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Procédés de préparation de dérivés de benzyl-benzène substitués par un glucopyranosyle
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2812519A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
PT2981271T (pt) * 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
DK2986304T3 (da) * 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.

Also Published As

Publication number Publication date
MX2023000796A (es) 2023-02-27
PH12019501018A1 (en) 2019-12-16
CL2019001214A1 (es) 2019-07-26
BR112019008384A2 (pt) 2019-07-09
AU2017357589A1 (en) 2019-04-18
EP3538107A1 (fr) 2019-09-18
US20220288012A1 (en) 2022-09-15
AU2017357589B2 (en) 2023-05-11
WO2018087132A1 (fr) 2018-05-17
AU2023203321A1 (en) 2023-06-22
CA3039745A1 (fr) 2018-05-17
JP2019533709A (ja) 2019-11-21
JP2023010710A (ja) 2023-01-20
MX2019005435A (es) 2019-07-10
KR20190084096A (ko) 2019-07-15
US20180125813A1 (en) 2018-05-10
CN109922813A (zh) 2019-06-21
KR20230162125A (ko) 2023-11-28
US20200138770A1 (en) 2020-05-07
US20210228533A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA46742A (fr) Composition pharmaceutique, méthodes de traitement et leurs utilisations
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA51155A (fr) Compositions comprenant des polyribonucléotides circulaires et leurs utilisations
MA43172A (fr) Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA43190A (fr) Traitement de la dyslipidémie mixte
EA201890204A1 (ru) Антибактериальные соединения
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA42624A (fr) Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
MA46945A (fr) Exopolysaccharides et leurs utilisations
MA49633A (fr) Agents, utilisations et procédés de traitement
MA41864A (fr) Variants de protoxine ii et leurs méthodes d'utilisation
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina